Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, Murray C, Logie A, Revill M, Byth KF, Benjamin AD, Firth MA, Green S, Smith PD, Critchlow SE.

Oncotarget. 2017 May 25;8(41):69219-69236. doi: 10.18632/oncotarget.18215. eCollection 2017 Sep 19.

2.

A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055.

Yates JWT, Holt SV, Logie A, Payne K, Woods K, Wilkinson RW, Davies BR, Guichard SM.

Br J Pharmacol. 2017 Aug;174(16):2652-2661. doi: 10.1111/bph.13886. Epub 2017 Jul 6.

3.

skn-1 is required for interneuron sensory integration and foraging behavior in Caenorhabditis elegans.

Wilson MA, Iser WB, Son TG, Logie A, Cabral-Costa JV, Mattson MP, Camandola S.

PLoS One. 2017 May 1;12(5):e0176798. doi: 10.1371/journal.pone.0176798. eCollection 2017.

4.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.

Bradford JR, Wappett M, Beran G, Logie A, Delpuech O, Brown H, Boros J, Camp NJ, McEwen R, Mazzola AM, D'Cruz C, Barry ST.

Oncotarget. 2016 Apr 12;7(15):20773-87. doi: 10.18632/oncotarget.8014.

5.

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL.

Mol Cancer Ther. 2015 Nov;14(11):2441-51. doi: 10.1158/1535-7163.MCT-15-0230. Epub 2015 Sep 8.

6.

Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.

Keen HG, Ricketts SA, Maynard J, Logie A, Odedra R, Shannon AM, Wedge SR, Guichard SM.

Mol Imaging Biol. 2014 Jun;16(3):421-30. doi: 10.1007/s11307-013-0705-0.

PMID:
24249640
7.

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26.

PMID:
23355042
8.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

9.

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard SM, Smith PD.

Cancer Res. 2012 Apr 1;72(7):1804-13. doi: 10.1158/0008-5472.CAN-11-1780. Epub 2012 Jan 23.

10.

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Marshall G, Howard Z, Dry J, Fenton S, Heathcote D, Gray N, Keen H, Logie A, Holt S, Smith P, Guichard SM.

Biochem Soc Trans. 2011 Apr;39(2):456-9. doi: 10.1042/BST0390456. Review.

PMID:
21428919
11.

The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.

Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR.

Clin Cancer Res. 2009 Nov 1;15(21):6619-29. doi: 10.1158/1078-0432.CCR-08-2958. Epub 2009 Oct 20.

12.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.

Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF.

Mol Oncol. 2009 Jun;3(3):248-61. doi: 10.1016/j.molonc.2009.01.002. Epub 2009 Feb 7.

14.
15.

Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.

Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F.

Hum Mol Genet. 2005 May 1;14(9):1153-60. Epub 2005 Mar 16.

PMID:
15772091
16.

[Involvement of the IGF system in the pathogenesis of adrenocortical tumors].

Gicquel C, Boulle N, Logié A, Bourcigaux N, Gaston V, Le Bouc Y.

Ann Endocrinol (Paris). 2001 Apr;62(2):189-92. Review. French.

PMID:
11353893
17.

Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors.

Boulle N, Baudin E, Gicquel C, Logié A, Bertherat J, Penfornis A, Bertagna X, Luton JP, Schlumberger M, Le Bouc Y.

Eur J Endocrinol. 2001 Jan;144(1):29-36.

PMID:
11174834
18.

Establishment and characterization of a human adrenocortical carcinoma xenograft model.

Logié A, Boudou P, Boccon-Gibod L, Baudin E, Vassal G, Schlumberger M, Le Bouc Y, Gicquel C.

Endocrinology. 2000 Sep;141(9):3165-71.

PMID:
10965887
20.

Alterations of the 11p15 imprinted region and the IGFs system in a case of recurrent non-islet-cell tumour hypoglycaemia (NICTH).

Bertherat J, Logié A, Gicquel C, Mourriéras F, Luton JP, Le Bouc Y.

Clin Endocrinol (Oxf). 2000 Aug;53(2):213-20.

PMID:
10931103
21.

High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.

Bourcigaux N, Gaston V, Logié A, Bertagna X, Le Bouc Y, Gicquel C.

J Clin Endocrinol Metab. 2000 Jan;85(1):322-30.

PMID:
10634406
22.

African AIDS conference offers hope for the future.

Logie AW.

Lancet. 1999 Sep 25;354(9184):1104.

PMID:
10509513
23.

Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.

Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, Gicquel C.

J Mol Endocrinol. 1999 Aug;23(1):23-32.

PMID:
10425444
24.
25.

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors.

Boulle N, Logié A, Gicquel C, Perin L, Le Bouc Y.

J Clin Endocrinol Metab. 1998 May;83(5):1713-20.

PMID:
9589681
26.

Women's reproductive health. Pregnancy causing a "silent slaughter" in the developing world.

Logie DE, Logie AW.

BMJ. 1994 Mar 19;308(6931):790. No abstract available.

27.

A flexible loading dose schedule for warfarin therapy.

Fergusson RJ, Eade OE, Logie AW, Gaddie J.

Scott Med J. 1987 Dec;32(6):169-71.

PMID:
3329767
28.

Fatal overdosage of phenylpropanolamine.

Logie AW, Scott CM.

Br Med J (Clin Res Ed). 1984 Sep 8;289(6445):591. No abstract available.

29.

The nature of iron released by resident and stimulated mouse peritoneal macrophages.

Brock JH, Esparza I, Logie AC.

Biochim Biophys Acta. 1984 Jan 24;797(1):105-11.

PMID:
6692005
30.

Status epilepticus treated by barbiturate anaesthesia.

Logie AW, Christian PS.

Br Med J (Clin Res Ed). 1981 Mar 21;282(6268):991. No abstract available.

31.

Drug interactions and long-term antidiabetic therapy.

Logie AW, Galloway DB, Petrie JC.

Br J Clin Pharmacol. 1976 Dec;3(6):1027-32.

32.

A relationship between functional age and health status in female subjects.

Webster IW, Logie AR.

J Gerontol. 1976 Sep;31(5):546-50.

PMID:
950448
33.

Propranolol in hypertension: a dose-response study.

Galloway DB, Glover SC, Hendry WG, Logie AW, Petrie JC, Smith MC, Lewis JA, Simpson WT.

Br Med J. 1976 Jul 17;2(6028):140-2.

34.

Hazards of monocomponent insulins.

Logie AW, Stowers JM.

Br Med J. 1976 Apr 10;1(6014):879-80. No abstract available.

35.

Patient evaluation of a computerised questionnaire.

Logie AR, Madirazza JA, Webster IW.

Comput Biomed Res. 1976 Apr;9(2):169-76. No abstract available.

PMID:
1269254
36.

A volunteer crisis service. Pattern of utilization and referral.

Webster IW, Crews W, Logie AR.

Med J Aust. 1975 Oct 18;2(16):630-4.

PMID:
1207540
37.

Clinical trial of glibornuride in diabetes.

Logie AW, Stowers JM.

Br Med J. 1975 Aug 30;3(5982):514-5.

38.

Prolonged-action fenfluramine in non-diabetic patients with refractory obesity.

Galloway DB, Logie AW, Petrie JC.

Postgrad Med J. 1975;51 Suppl 1:155-7. No abstract available.

PMID:
768957
39.

Longitudinal study of untreated chemical diabetes.

Logie AW, Stowers JM, Dingwall-Fordyce I.

Br Med J. 1974 Dec 14;4(5945):630-2.

40.

An assessment of aging based on screening data.

Webster IW, Logie AR.

J Am Geriatr Soc. 1974 Aug;22(8):360-4. No abstract available.

PMID:
4850516
41.

A computer based system for handling radiological and thermographic data.

Porter TJ, Logie AR, Ryan JF, Webster IW.

Australas Radiol. 1973 Mar;17(1):78-90. No abstract available.

PMID:
4732243
42.

The sensitivity of spirometry to the symptoms of respiratory disease.

Webster IW, Logie AR.

Respiration. 1973;30(6):517-28. No abstract available.

PMID:
4762246
43.

Diagnostic cytology.

Logie AR, Webster IW.

Med J Aust. 1972 Jul 29;2(5):281. No abstract available.

PMID:
5076006
44.

Antigenic changes during the life cycle of Plasmodium falciparum.

Beck JS, Logie AW, McGregor IA.

Experientia. 1970 Dec 15;26(12):1365-6. No abstract available.

PMID:
4923734
45.

Plasmodium falciparum in ascitic fluid.

Logie AW, Beck JS.

Trans R Soc Trop Med Hyg. 1970;64(6):829-33. No abstract available.

PMID:
4924647
46.

Acute rheumatic carditis and subacute bacterial endocarditis in pregnancy.

LOGIE AJ, HOWDON WM.

J Fla Med Assoc. 1954 May;40(11):808-13. No abstract available.

PMID:
13152313

Supplemental Content

Support Center